New York, United States, March 07, 2023 (GLOBE NEWSWIRE) -- Myocardial Infarction or heart attack is a condition when blood flow at a heart muscle stops or decreases. The condition may occur due to various reasons, including excessive smoking, unhealthy food habits, and others. It is more common in elderly people and may lead to death. Many treatment methods are available for the condition including various types of drugs and drug classes, surgeries, and others. All the treatment methods may differ from individual to individual. High chances of reoccurrence are the major factors leading to the increasing usage of prevention and treatment drugs.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/myocardial-infarction-market/request-sample
Increasing research and development activities for safe drug development
Increasing research and development activities and growing technological advancements by various companies and government organizations are creating lucrative opportunities for market players. Various companies are emphasizing on developing innovative drugs. For instance, Novartis has developed a drug called canakinumab (ACZ885). It helps to prevent heart attacks by controlling inflammation—a different approach than lowering cholesterol level. According to Novartis, it reduced the cardiovascular risk by 25% in the trial presented at American Heart Association Session 2017.
Report Scope
| Report Metric | Details |
| Market Size | USD 3.85 billion by 2030 |
| CAGR | 8% (2023-2031) |
| Historical Data | 2019-2020 |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Distribution Channel |
| Geographies Covered | North America, Europe, Asia-Pacific, LAME, and Rest of the World |
| Key Companies Profiled/Vendors | Apotex Inc., AstraZeneca, Bayer AG, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Daiichi Sankyo Co. Ltd., Mylan N.V., Novartis AG, Par Pharmaceutical Companies Inc., Pfizer Inc |
| Key Market Drivers | Increasing research and development activities for safe drug development |
Buy Now Full Report @ https://straitsresearch.com/buy-now/myocardial-infarction-market
Asia Pacific is the fastest-growing region in the forecast period
Myocardial infarction is one of the major diseases in China. It has become the major cause of an emergency over the past few decades owing to changing lifestyle and declining physical activity. In China, of men aged 30–44 years who die from cardiovascular disease, 46% of these deaths are attributable to tobacco. Additionally, there are more than 300 million smokers in China, nearly one-third of the world's total smoking population. This is projected to increase the risk of developing cardiovascular diseases, which is also expected to increase the demand for their demand. Thus, China is projected to witness considerable growth in the market during the forecast period.
Competitive Landscape
Daiichi Sankyo, Co. Ltd is one of the leading providers of the medical solution of various segments including cardiovascular diseases such as myocardial infarction or heart attack and angina, kidney disease, and oncology segment across the globe. The company is differentiating itself with continuous innovations and expansion in various regions. Several products such as Efient and Ovisot have been launched by the company for the treatment of heart diseases over the last few years. The products have helped the company to strengthen its position in the market and also, to expand their product portfolio related to heart attack and other diseases.
Some of the prominent players in the market are
- Apotex Inc.
- AstraZeneca
- Bayer AG
- Boehringer-Ingelheim
- Bristol-Myers Squibb Company
- Daiichi Sankyo Co. Ltd.
- Mylan N.V.
- Novartis AG
- Par Pharmaceutical Companies Inc.
- Pfizer Inc.
Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/myocardial-infarction-market/request-sample
Global Myocardial Infarction Market Segmentation
By Product Type
- Analgesics
- Antiplatelet agents
- Vasodilators
- Thrombolytics and anti-thrombotic agents
- Glycoprotein IIb/IIIa inhibitors
- Β adrenergic blockers
- Angiotensin receptor antagonists
- Angiotensin converting enzyme inhibitors
By Distribution channel
- Hospitals
- Hospital Pharmacies
- Drug Stores
- Online drug stores
Regions Covered
- America
- North America
- U.S.
- Canada
- Mexico
- South America
- Europe
- Western Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Eastern Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East
- Saudi Arabia
- UAE
- Qatar
- Rest of The Middle East
- Africa
- South Africa
- Ghana
- Nigeria
Table of Contents
- Executive Summary
- Research Scope & Segmentation
- Research Objectives
- Market Definition
- Limitations & Assumptions
- Market Scope & Segmentation
- Currency & Pricing Considered
- Market Opportunity Assessment
- Emerging Regions / Countries
- Emerging Companies
- Emerging Applications / End Use
- Investment Landscape
- New Business Models / Revenue Streams
- TAM
- Market Trends
- Drivers
- Market Warning Factors
- Latest Macro Economic Indicators
- Geopolitical Impact
- Human Factors
- Technology Factors
- Market Assessment
- Porters Five Forces Analysis
- Value Chain Analysis
- Sales And Distribution Channel Analysis
- Case Study Analysis
- Patent Analysis
- M & A Agreements & Collabration Analysis
- ESG Trends
- Global Myocardial Infarction Market Size Analysis
- Global Myocardial Infarction Market Introduction
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- North America Market Analysis
- Introduction
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- U.S.
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- By Product Type
- Canada
- Europe Market Analysis
- Introduction
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- U.K.
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- By Product Type
- Germany
- France
- Spain
- Italy
- Russia
- Nordic
- Benelux
- Rest Of Europe
- Apac Market Analysis
- Introduction
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- China
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- By Product Type
- Korea
- Japan
- India
- Australia
- Taiwan
- South East Asia
- Rest Of Asia-Pacific
- Middle East And Africa Market Analysis
- Introduction
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- UAE
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- By Product Type
- Turkey
- Saudi Arabia
- South Africa
- Egypt
- Nigeria
- Rest Of MEA
- LATAM Market Analysis
- Introduction
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- Brazil
- By Product Type
- Introduction
- Product Type By Value
- Analgesics
- By Value
- Antiplatelet Agents
- By Value
- Vasodilators
- By Value
- Thrombolytics And Anti-Thrombotic Agents
- By Value
- Glycoprotein IIb/IIIa Inhibitors
- By Value
- Β Adrenergic Blockers
- By Value
- Angiotensin Receptor Antagonists
- By Value
- Angiotensin Converting Enzyme Inhibitors
- By Value
- Introduction
- By Distribution Channel
- Introduction
- Distribution Channel By Value
- Hospitals
- By Value
- Hospital Pharmacies
- By Value
- Drug Stores
- By Value
- Online Drug Stores
- By Value
- Introduction
- By Product Type
- Mexico
- Argentina
- Chile
- Colombia
- Rest Of LATAM
- Competitive Assessment
- Adoption Matrix
- Myocardial Infarction Market Share By Manufacturers
- Myocardial Infarction Market Ranking By Revenue For Manufacturers
- Average Price By Manufacturers
- Vendor Footprint Analysis
- Market Players Assessment
- Apotex Inc.
- Overview
- Business Information
- Revenue
- ASP
- Gross Margin
- Swot Analysis
- Recent Developmments
- AstraZeneca
- Bayer AG
- Boehringer-Ingelheim
- Bristol-Myers Squibb Company
- Daiichi Sankyo Co. Ltd.
- Mylan N.V.
- Novartis AG
- Par Pharmaceutical Companies Inc.
- Pfizer Inc.
- Apotex Inc.
- Research Methodology
- Research Data
- Secondary Data
- Major Secondary Sources
- Key Data From Secondary Sources
- Primary Data
- Key Data From Primary Sources
- Breakdown Of Primaries
- Secondary And Primary Research
- Key Industry Insights
- Secondary Data
- Market Size Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Projection
- Research Assumptions
- Assumptions
- Limitations
- Risk Assessment
- Research Data
- APPENDIX
- Discussion Guide
- Customization Options
- Related Reports
- DISCLAIMER
Table of Content @ https://straitsresearch.com/report/myocardial-infarction-market/toc
News Media
Myocardial Infarction Market was Valued at USD 1,530.7 million in 2018, at a CAGR of 8.0%.
Have a Look at the Related Research Report
Cardiovascular Ultrasound (CVUS) Market: Information by Type (Transthoracic Echocardiography), Technology (2D, 3D/4D, Doppler (Display: B/W, Color)), End-Use, and Region – Forecast till 2030
Cardiovascular Needle Market: Information by Type (Round-bodied needles, Cutting needles), Application (Open heart surgery, Cardiac valve procedures), and Region- Forecast till 2030
Heart Pump Device Market: Information by Product (Ventricular Assist Devices, Intra-Aortic Balloon Pumps), Type (Implantable Heart Pump Devices), Therapy, and Region — Forecast till 2031
Coronary Heart Disease Diagnostic Imaging Devices Market: Information by Modality (Computed Tomography, X rays), and Region- Forecast till 2030
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
Phone: +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
Email: sales@straitsresearch.com
Follow Us: LinkedIn | Facebook | Instagram | Twitter
